tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Sports

tanzania times : Latest News and In-depth Analysis
HomeSports
Sports

Feb 16, 2026

CYCJET: Providing innovative marking solutions for industrial intelligence along the Belt and Road Initiative.

CYCJET: Providing innovative marking solutions for industrial intelligence along the Belt and Road Initiative.

All News

Full Truck Alliance Co. Ltd. to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on Wednesday, March 5, 2025

Earnings Call Scheduled for 7:00 A.M. U.S. ET on March 5,2025 GUIYANG,China,Feb. 14,2025-- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM),a leading digital freig

Feb 17, 2025

Zeekr Group Announces the Closing of Strategic Integrated Transactions

HANGZHOU,China,Feb. 14,2025-- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK),the world\'s leading premium new energy vehicle group,today a

Feb 17, 2025

Sports

First Drone Show by Soiree Rooftop Bar, Lights Up Surabaya's Skyline

SURABAYA,Indonesia,Feb. 14,2025--A night of enchantment and cultural splendor unfolded at Soirée Rooftop Bar as The 1st Drone Show & Lunar Party illuminated the Surabaya skyline in a breath

Feb 17, 2025

Sports

ATxEnterprise 2025 Celebrates Five Years of Powering Enterprise Technology, Cybersecurity, and Digital Transformation

SINGAPORE,Feb. 14,2025-- ATxEnterprise (ATxE) 2025,a flagship event of Asia Tech x Singapore (ATxSG),returns for its fifth year,providing a strategic platform for enterprises,governments,and technolo

Feb 17, 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi

Feb 14, 2025

Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa

The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial.

Feb 14, 2025

1 ... 71 72 73 74 75 76 77 ... 115